SPY333.83-0.50 -0.15%
DIA273.24-0.67 -0.24%
IXIC11,056.47-51.60 -0.46%
AcelRx to Host Second Quarter 2020 Financial Results Call and Webcast on Monday, August 10th, 2020
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 10, 2020. AcelRx management will host a live webcast and conference call
PR Newswire · 3d ago
Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q2 Earnings Expected to Decline
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/27 16:31
AcelRx announces equity raise of $10M
AcelRx Pharmaceuticals (ACRX +6.1%) enters into an agreement with Armistice Capital and Rock Springs Capital for the sale of 9.4M shares at $1.06/share, fo
seekingalpha · 07/23 20:17
AcelRx Announces Exclusive Distribution, Promotion Partnership For DSUVIA
Benzinga · 07/23 12:41
AcelRx Announces Exclusive Distribution and Promotion Partnership for DSUVIA®
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced an agreement to market DSUVIA®, a sublingual opioid tablet in a single-dose applicator, within the dental and oral surgery markets in the United States exclusively
PR Newswire · 07/23 12:40
AcelRx Prices 9.43M Share Offering At $1.06/Share
Benzinga · 07/23 12:32
AcelRx Announces $10 Million Common Stock Offering Priced At The Market
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced it has entered into an agreement with funds af
PR Newswire · 07/23 12:30
80 Biggest Movers From Friday
Gainers Berkeley Lights, Inc. (NASDAQ: BLI) shares jumped 197.5% to close at $65.45 on Friday after the company priced its 8.1 million share IPO at $22 per share.
Benzinga · 07/20 09:11
Credit Suisse Downgrades AcelRx Pharmaceuticals to Underperform, Lowers Price Target to $0.69
Credit Suisse analyst Evan Seigerman downgrades AcelRx Pharmaceuticals (NASDAQ:ACRX) from Neutral to Underperform and lowers the price target from $1 to $0.69.
Benzinga · 07/20 09:09
AcelRx Wins ~$3.5M US Army Medical Research Acquisition Contract For Dsuvia
Benzinga · 07/16 21:33
Atlas Technical Consultants Sees Prelim. Q2 Sales $111M-$113M vs $109.25M Est.; Sees FY19 Sales $453M-$468M vs $460.31M Est.
Benzinga · 07/14 11:12
AcelRx: Clever Solution To Painful Problem
Seeking Alpha - Article · 06/26 21:26
Edited Transcript of ACRX.OQ earnings conference call or presentation 11-May-20 8:30pm GMT
Q1 2020 AcelRx Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents · 06/23 02:11
La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) seems to be far from over.
Benzinga · 06/22 16:14
La Jolla Pharma makes unsolicited bid for Tetraphase Pharma
Seeking Alpha - Article · 06/22 10:33
Trade Alert: The Independent Chairman Of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), Adrian Adams, Has Just Spent US$129k Buying 133% More Shares
Simply Wall St. · 06/17 11:33
Melinta inks agreement for Tetraphase buy
Seeking Alpha - Article · 06/09 20:25
Edited Transcript of ACRX earnings conference call or presentation 16-Mar-20 12:30pm GMT
Thomson Reuters StreetEvents · 06/08 19:45
Merger Arbitrage Mondays - Tiffany Experiences Wild Gyrations
Seeking Alpha - Article · 06/08 13:42
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Benzinga · 06/04 13:13